Project Grant R01CA300054
Award Date 9/2/26
Completion Date 8/31/31
Dollars Obligated $569K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Augusta, GA 30912, USA
Similar Awards
- The National Cancer Institute awarded The Medical University of South Carolina $531,584 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate heat shock protein 70 (HSP70) as a therapeutic target in pancreatic ductal adenocarcinoma. The research identifies HSP70, a stress-inducible molecular chaperone markedly overexpressed in primary and metastatic pancreatic cancer, as a selective therapeutic vulnerability. The investigator team developed a...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Rochester $624,494 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate combined stereotactic body radiotherapy and interleukin-12 messenger RNA nanotechnology as a treatment strategy for pancreatic ductal adenocarcinoma. The research targets T cell dynamics in the pancreatic cancer tumor microenvironment by combining localized stereotactic body...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $633,089 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate a novel cell stress response mechanism in pancreatic ductal adenocarcinoma (PDAC) that enables cancer cells to adapt to adverse microenvironmental conditions and evade immune surveillance. The research will identify and characterize immunotherapeutic...
- The National Cancer Institute awarded Augusta University Research Institute, Inc. $395,973 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct the CROSS (Cancer at the Crossroads) project, a population-based epidemiologic study evaluating how area-level social determinants of health impact early-onset colorectal cancer (EOCRC) outcomes. The project integrates Surveillance, Epidemiology, and End Results (SEER) 17 incidence data linked with county...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded Emory University $402,401 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate ionizing radiation as a sensitizing agent for HER2-targeted antibody-drug conjugate therapy in breast cancers with low or absent HER2 expression. The research employs established cell culture and circulating tumor cell models to test whether ionizing...
- The National Cancer Institute, a division of the Department of Health and Human Services National Institutes of Health, awarded Health Research, Inc. (Roswell Park Division) $446,112 on July 3, 2026, under the Cancer Biology Research program (CFDA 93.396) to identify age-regulating breast cancer dormancy genes using C. elegans dauer models. The project investigates how chronological aging of dormant cancer cells drives metastatic relapse and reawakening after initial treatment. The recipient...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Texas at Austin $396,377 on May 7, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize mutational signatures at hotspots of genetic instability in human cancer genomes. The project integrates large-scale cancer genome analyses, gene perturbation experiments, and environmental mutagen exposure data to uncover the mutational processes driving...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $595,041 to Georgia TECH Research Corp on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate redox and lipid metabolism as determinants of radiotherapy resistance in head and neck cancer. The award funds research examining how targeted disruption of tumor redox and lipid metabolism through molecular therapies and dietary intervention can...
- The National Cancer Institute awarded the University of Miami $522,368 on August 11, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate how RNA polymerase II bypasses transcription-blocking lesions caused by ultraviolet radiation and the role of transcription-coupled nucleotide excision repair (TC-NER) in this process. The research aims to understand how the acetyltransferase P300 regulates RNA polymerase II stalling at UV-induced DNA lesions, how its...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded New York University $701,574 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate APOBEC3-induced mutagenesis in cancer development and therapy resistance. The funded research develops experimental and bioinformatics methods to track de novo generation of specific mutational signatures (SBS2 and SBS13) induced by individual...